NCT01906255View on ClinicalTrials.gov

Adherence, HIV-1 Infection, Resistance, and Renal and Skeletal Adverse Event in Individuals Taking Truvada® for HIV Pre-Exposure Prophylaxis (PrEP)

CompletedOBSERVATIONAL

Enrollment

10,577

Participants

Timeline

Start Date

October 7, 2013

Primary Completion Date

April 27, 2021

Study Completion Date

April 27, 2021

Conditions

HIV

Trial Locations (1)

94404

Gilead Sciences, Inc., Foster City

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY